CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

Launched by UNIVERSITY OF WISCONSIN, MADISON · Feb 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of Cannabidiol (CBD), a compound found in cannabis, on urinary incontinence and other urinary symptoms in people who have recently suffered a spinal cord injury. The researchers want to find out if taking Epidiolex, a purified form of CBD, for 90 days can help improve these symptoms in participants with a specific type of spinal cord injury.

To participate in this study, individuals must be at least 18 years old, have a history of a spinal cord injury above the sacral region, and experience at least two episodes of urinary incontinence each day. Participants should be willing to take the study medication and be able to speak English to provide consent and complete questionnaires. It’s important to note that those with certain medical histories, such as previous use of Botox for bladder issues or specific medications, may not be eligible. The trial is not yet recruiting participants, but if you meet the criteria, this could be an opportunity to explore a new treatment option for managing urinary incontinence after a spinal cord injury.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • \>18 years of age
• • History of supra-sacral spinal cord injury of any mechanism
• • Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock)
• • Willingness to participate in drug intervention trial
• • English-speaking (able to provide consent and complete questionnaires)
• Exclusion Criteria:
• • History of intravesical Botox
• • Actively taking \>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms
• • Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported
• • Thought or mood disorder aside from depression